ArticleWorld journal of gastroenterology2020
Evaluation of
Article in World journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Survival predictors ofJournal of cancer research and clinical oncology · 2022Trial
- Semiquantitative SSTR PET metrics show molecular-morphologic discordance after 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine neoplasms: an exploratory paired target-lesion analysis.Annals of nuclear medicine · 2026Article
- Evaluating the impact of Lutetium-177 therapy on bioprosthetic heart valves in carcinoid heart disease.Cardio-oncology (London, England) · 2026Article
- Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients.Journal of neuroendocrinology · 2025Article
- Radiomics Analysis for Clinical Decision Support in 177Lu-DOTATATE Therapy of Metastatic Neuroendocrine Tumors using CT Images.Journal of biomedical physics & engineering · 2024Article
- Short-Term Biological Toxicity Prediction of [Cancer biotherapy & radiopharmaceuticals · 2024Observational
- Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2024Review
- Peptide Receptor Radionuclide Therapy UsingWorld journal of nuclear medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
aimTo determine the impact of PRRT on quality of life, radiologic and metabolic response, overall survival, prognostic factors and toxicity.
methodsThirty-six patients treated with
resultsFrom 36 patients, 55.6% were men, with a median age of 61.1 ± 11.8 years. Regarding previous treatments, 55.6% of patients underwent surgery of the primary tumor, 100% of patients were treated with long-acting somatostatin analogues, 66.7% of patients were treated with everolimus, 27.8% of patients were treated with tyrosine kinase inhibitor, and 27.8% of patients were treated with interferon. One patient received radioembolization, three patients received chemoembolization, six patients received chemotherapy. Hematological toxicity was registered in 14 patients (G1-G2: 55.5% and G3: 3.1%). Other events presented were intestinal suboclusion in 4 cases, cholestasis in 2 cases and carcinoid crisis in 1 case. The median follow-up time was 3 years. Currently, 24 patients completed treatment. Nineteen are alive with stable disease, two have disease progression, eight have died, and nine are still receiving treatment. The median overall survival was 12.5 mo (95% confidence interval range: 9.8-15.2), being inversely proportional to toxicity in previous treatments (
conclusionOverall survival was inversely proportional to previous toxicity, tumor grade and the presence of bone metastasis and directly proportional to matching lesion findings between Octreoscan and computed tomography pre-PRRT and primary tumor and metastasis surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.